Kiora Net Income

KPRX
 Stock
  

USD 3.68  0.13  3.66%   

Kiora Pharmaceuticals fundamentals help investors to digest information that contributes to Kiora Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kiora Stock. The fundamental analysis module provides a way to measure Kiora Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiora Pharmaceuticals stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Kiora Net Income Analysis

Kiora Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Net Income 
 = 
(Rev + Gain) 
-  
(Exp + Loss) 
More About Net Income | All Equity Analysis

Current Kiora Pharmaceuticals Net Income

    
  (16.39 M)  
Most of Kiora Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kiora Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Compare to competition

Based on the recorded statements, Kiora Pharmaceuticals reported net income of (16.39 Million). This is 104.8% lower than that of the Healthcare sector and 123.41% lower than that of the Biotechnology industry. The net income for all United States stocks is 102.87% higher than that of the company.

Kiora Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Kiora Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kiora Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kiora Pharmaceuticals' value.
Security TypeSharesValue
Xtx Topco LtdCommon Shares13.9 K31 K
Wells Fargo CompanyCommon Shares5.00.0
Wells Fargo CompanyCommon Shares85.00.0
Wells Fargo CompanyCommon Shares78.00.0
Wells Fargo CompanyCommon Shares78.00.0
Wells Fargo CompanyCommon Shares77.00.0
Wells Fargo CompanyCommon Shares40.00.0

Kiora Fundamentals

About Kiora Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kiora Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kiora Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kiora Pharmaceuticals' short interest history, or implied volatility extrapolated from Kiora Pharmaceuticals options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kiora Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Kiora Pharmaceuticals Piotroski F Score and Kiora Pharmaceuticals Altman Z Score analysis. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Kiora Pharmaceuticals price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Is Kiora Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. If investors know Kiora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiora Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.1 M
Return On Assets
(0.29) 
Return On Equity
(1.24) 
The market value of Kiora Pharmaceuticals is measured differently than its book value, which is the value of Kiora that is recorded on the company's balance sheet. Investors also form their own opinion of Kiora Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiora Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiora Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiora Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiora Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Kiora Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiora Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.